
Could this peanut allergy drug open up a $4 billion market?
Melbourne biotech Aravax is in the middle of peanut allergy drug trials which, if successful, promise to open up an estimated US$4-billion global market. In a Nutshell It takes courage to tackle peanut allergy. In the 1990s, a child died during a clinical trial after an injection of peanut extract. It was a dosing error, […]